ACHL
- Achilles Therapeutics plc
()
Overview
Company Summary
Achilles Therapeutics plc is a biopharmaceutical company specializing in the development of personalized T-cell therapies for cancer treatment. The company focuses on targeting solid tumors by using the patient's own immune system to fight cancer.
Achilles Therapeutics utilizes a unique approach called clonal neoantigen targeting. By analyzing genetic mutations within a patient's tumor cells, the company identifies specific neoantigens � proteins that are present on cancer cells but not on healthy cells. These neoantigens serve as targets for the patient's T-cells, which are a type of white blood cell responsible for recognizing and destroying abnormal cells within the body.
Using this information, Achilles Therapeutics develops personalized T-cell therapies for each individual patient. The process involves extracting T-cells from the patient's blood and engineering them to specifically target the identified neoantigens. These genetically modified T-cells are then expanded in the laboratory and infused back into the patient, where they can recognize and destroy cancer cells with the targeted neoantigens.
The company's goal is to provide an innovative and effective treatment option for patients with solid tumors, such as lung, colorectal, and bladder cancers. By harnessing the power of the immune system and tailoring therapies to individual patients, Achilles Therapeutics aims to improve outcomes and potentially revolutionize cancer treatment.